184 related articles for article (PubMed ID: 8353584)
1. Clinical safety and cost of heparin titration using bedside activated clotting time.
Thomason T; Riegel B; Jessen D; Smith SC; Gocka I; Rich M
Am J Crit Care; 1993 Jan; 2(1):81-7. PubMed ID: 8353584
[TBL] [Abstract][Full Text] [Related]
2. Research review: use of activated clotting time to monitor heparin therapy in coronary patients.
Noureddine SN
Am J Crit Care; 1995 Jul; 4(4):272-7; quiz 278-9. PubMed ID: 7663590
[TBL] [Abstract][Full Text] [Related]
3. Heparin monitoring in the coronary care unit after percutaneous transluminal coronary angioplasty.
Varah N; Smith J; Baugh RF
Heart Lung; 1990 May; 19(3):265-70. PubMed ID: 2341265
[TBL] [Abstract][Full Text] [Related]
4. Activated clotting time differential is a superior method of monitoring anticoagulation following coronary angioplasty.
Pitney MR; Kelly SA; Allan RM; Giles RW; McCredie M; Walsh WF
Cathet Cardiovasc Diagn; 1996 Feb; 37(2):145-50. PubMed ID: 8808069
[TBL] [Abstract][Full Text] [Related]
5. Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time.
Nath FC; Muller DW; Rosenschein U; Ellis SG; Topol EJ
Can J Cardiol; 1993 Nov; 9(9):797-801. PubMed ID: 8281479
[TBL] [Abstract][Full Text] [Related]
6. [-Value of activated blood coagulation time in monitoring anticoagulation during coronary angioplasty-].
Kunert M; Sorgenicht R; Scheuble L; Ketteler T; Lürken E; Meyer I; Müller A; Emmerich K; Gülker H
Z Kardiol; 1996 Feb; 85(2):118-24. PubMed ID: 8650981
[TBL] [Abstract][Full Text] [Related]
7. Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation.
Maul TM; Wolff EL; Kuch BA; Rosendorff A; Morell VO; Wearden PD
Pediatr Crit Care Med; 2012 Nov; 13(6):e363-71. PubMed ID: 22940857
[TBL] [Abstract][Full Text] [Related]
8. Clotting, activated partial thromboplastin and coagulation times in monitoring heparin therapy.
Kurec AS; Morris MW; Davey FR
Ann Clin Lab Sci; 1979; 9(6):494-500. PubMed ID: 518012
[TBL] [Abstract][Full Text] [Related]
9. Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention.
Chen WH; Lau CP; Lau YK; Ng W; Lee PY; Yu CM; Ma E
J Invasive Cardiol; 2002 Aug; 14(8):439-42. PubMed ID: 12147872
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of drawing coagulation samples from heparinized arterial lines.
Templin K; Shively M; Riley J
Am J Crit Care; 1993 Jan; 2(1):88-95. PubMed ID: 8353585
[TBL] [Abstract][Full Text] [Related]
11. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
[TBL] [Abstract][Full Text] [Related]
12. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*.
Liveris A; Bello RA; Friedmann P; Duffy MA; Manwani D; Killinger JS; Rodriquez D; Weinstein S
Pediatr Crit Care Med; 2014 Feb; 15(2):e72-9. PubMed ID: 24335992
[TBL] [Abstract][Full Text] [Related]
13. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.
Marmur JD; Poludasu S; Feit A; Battala VR; Cavusoglu E
J Invasive Cardiol; 2008 Jul; 20(7):323-7. PubMed ID: 18599887
[TBL] [Abstract][Full Text] [Related]
14. Percutaneous transluminal coronary angioplasty: comparison of arterial vs. venous activated clotting time.
Pesola GR; Johnson A; Pesola DA
Cathet Cardiovasc Diagn; 1996 Feb; 37(2):140-4. PubMed ID: 8808068
[TBL] [Abstract][Full Text] [Related]
15. Prolonged heparin after uncomplicated coronary interventions: a prospective, randomized trial.
Garachemani AR; Kaufmann U; Fleisch M; Meier B
Am Heart J; 1998 Aug; 136(2):352-6. PubMed ID: 9704701
[TBL] [Abstract][Full Text] [Related]
16. The truth about activated clotting time measurements.
Bittl JA
Catheter Cardiovasc Interv; 2005 Jul; 65(3):338-9. PubMed ID: 15864807
[No Abstract] [Full Text] [Related]
17. [The use of activated clotting time (ACT) to optimize heparinization during coronary angioplasty. The nursing personnel of the Hemodynamics Laboratory].
Dellavalle A; Steffenino G; Ribichini F; Russo P; Conte L; Conte E; Uslenghi E
G Ital Cardiol; 1995 Apr; 25(4):445-51. PubMed ID: 7642051
[TBL] [Abstract][Full Text] [Related]
18. Venous activated clotting time after intra-arterial heparin: effect of site of administration and timing of sampling.
Kerensky RA; Azar GJ; Bertolet B; Hill JA; Kutcher MA
Cathet Cardiovasc Diagn; 1996 Feb; 37(2):151-3. PubMed ID: 8808070
[TBL] [Abstract][Full Text] [Related]
19. Monitoring anticoagulation following intracoronary procedures: which method?
Brack MJ; More RS; Forbat LN; Hubner PJ; Gershlick AH
Int J Cardiol; 1994 Jun; 45(2):103-8. PubMed ID: 7960247
[TBL] [Abstract][Full Text] [Related]
20. [The role of low-molecular-weight heparin in unstable angina, acute myocardial infarction and post-elective percutaneous transluminal coronary angioplasty].
Cláudio Correia LC; Neubauer C; Azevedo A; Ribeiro F; Braga J; Carlos Passos L; Teixeira M; Matos M; Aires V; Souza V
Arq Bras Cardiol; 1995 Dec; 65(6):475-8. PubMed ID: 8731298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]